Storia naturale della distrofia muscolare di Becker: in preparazione di futuri studi clinici
- 4.5 Anni 2022/2026
 - 456.200€ Totale Fondi
 
La distrofia muscolare di Becker (BMD) è una malattia neuromuscolare dovuta a un difetto parziale della proteina distrofina a livello del muscolo scheletrico e del cuore. Rispetto alla forma più grave, quella di Duchenne (DMD), in cui la distrofina manca completamente, la BMD è caratterizzata da un’ampia variabilità del quadro clinico. Una percentuale significativa di questi pazienti presenta debolezza e atrofia muscolari di grado severo, così come una cardiomiopatia potenzialmente letale. Rispetto alla DMD, la BMD è meno studiata e non altrettanto ben caratterizzata. Entrambe le malattie sono ancora prive di una cura definitiva; tuttavia, mentre per la DMD ci sono numerosi approcci terapeutici in corso di sperimentazione clinica, per la BMD gli studi clinici sui pazienti sono ancora pochi così come scarseggia la disponibilità di farmaci efficaci.
I trial clinici condotti finora sui pazienti con DMD hanno mostrato all’intera comunità neuromuscolare (pazienti, familiari, clinici, scienziati, industria farmaceutica) quanto sia importante disporre di misure di efficacia clinica solide e di una conoscenza approfondita della storia naturale della malattia, per esempio, per identificare gli indicatori più adatti per valutare l’andamento degli studi oppure per stimare il corretto numero di pazienti da coinvolgere. In effetti, proprio a causa di lacune di conoscenza in questo campo, diversi studi di fase 2 e 3 per la DMD hanno rischiato il fallimento, nonostante le ampie risorse investite. Alla luce di questa esperienza pregressa e visto il numero crescente di molecole promettenti per la cura della BMD, è urgente colmare l’attuale carenza conoscitiva sulla storia naturale di questa malattia. Questo permetterà di ottimizzare il disegno e l’interpretazione dei risultati dei futuri studi clinici sulla BMD che proprio per la maggiore variabilità clinica e per la più lenta progressione comporta difficoltà maggiori rispetto alla DMD nella conduzione di studi clinici di successo.
Obiettivo di questo progetto sarà quindi raccogliere dati sulla storia naturale della BMD a partire dalla solida esperienza pregressa della rete clinica neuromuscolare nel campo della DMD che ha già messo a punto protocolli comuni di valutazione dei pazienti e uniformato, per quanto possibile la cura clinica.
Pubblicazioni Scientifiche
- 2019 PLOS ONE 
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
 - 2016 EMBO MOLECULAR MEDICINE 
Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.
 - 2019 PLOS ONE 
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
 - 2016 Neuromuscular disorders : NMD 
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?
 - 2020 PHARMACOLOGICAL RESEARCH 
Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.
 - 2016 ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY 
Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy.
 - 2020 NEUROLOGY 
Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.
 - 2020 ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY 
Genetic modifiers of respiratory function in Duchenne muscular dystrophy.
 - 2016 ANNALS OF NEUROLOGY 
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
 - 2016 PLOS ONE 
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study.
 - 2019 MUSCLE & NERVE 
Expanding the central nervous system disease spectrum associated with FLNC mutation.
 - 2019 Journal of neurology, neurosurgery, and psychiatry 
Expanding the spectrum of genes responsible for hereditary motor neuropathies.
 - 2012 NATURE GENETICS 
Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia.
 - 2015 EUROPEAN JOURNAL OF HUMAN GENETICS 
The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy
 - 2019 ANNALS OF NEUROLOGY 
A multicenter retrospective study of charcot-marie-tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs).
 - 2015 Journal of the peripheral nervous system : JPNS 
A novel heat shock protein 27 homozygous mutation: widening of the continuum between MND/dHMN/CMT2.
 - 2020 FRONTIERS IN MOLECULAR NEUROSCIENCE 
LAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models.
 - 2014 ACTA MYOLOGICA 
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study
 - 2017 ACTA MYOLOGICA 
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions
 - 2017 ACTA MYOLOGICA 
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs
 - 2018 PLOS ONE 
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data.
 - 2019 Neuromuscular disorders : NMD 
Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment.
 - 2019 Neuromuscular disorders : NMD 
Longitudinal natural history in young boys with Duchenne muscular dystrophy.
 - 2018 NEUROLOGY 
The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy.
 - 2016 NEUROMUSCULAR DISORDERS 
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study
 - 2012 Molecular therapy : the journal of the American Society of Gene Therapy 
Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.
 - 2014 PLOS ONE 
6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes.
 - 2010 Neuromuscular disorders : NMD 
North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
 - 2009 Neuromuscular disorders : NMD 
Reliability of the North Star Ambulatory Assessment in a multicentric setting.
 - 2015 Neuromuscular disorders : NMD 
Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy.
 - 2016 Journal of neurology, neurosurgery, and psychiatry 
The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
 - 2014 Neuromuscular disorders : NMD 
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy.
 - 2015 Neuromuscular disorders : NMD 
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test.
 - 2014 JOURNAL OF NEUROLOGY 
"I have got something positive out of this situation": psychological benefits of caregiving in relatives of young people with muscular dystrophy.
 - 2018 PLOS ONE 
Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment?
 - 2017 Neuromuscular disorders : NMD 
Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements.
 - 2017 HUMAN MOLECULAR GENETICS 
Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway.
 - 2020 Journal of clinical medicine 
Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies.
 - 2020 ORPHANET JOURNAL OF RARE DISEASES 
Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.
 - 2021 Neuromuscular disorders : NMD 
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy.
 - 2020 FRONTIERS IN GENETICS 
Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy.
 - 2020 FRONTIERS IN GENETICS 
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study.
 - 2020 Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 
Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase.
 - 2019 FRONTIERS IN NEUROLOGY 
Advances in Quantitative Imaging of Genetic and Acquired Myopathies: Clinical Applications and Perspectives.
 - 2012 PLOS ONE 
Hyccin, the Molecule Mutated in the Leukodystrophy Hypomyelination and Congenital Cataract (HCC), Is a Neuronal Protein
 - 2012 NEUROGENETICS 
TRPV4 mutations in children with congenital distal spinal muscular atrophy
 - 2016 ORPHANET JOURNAL OF RARE DISEASES 
MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients
 - 2020 The Journal of pediatrics 
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
 - 2021 NEUROLOGY 
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.
 - 2020 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 
eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases.
 - 2020 MOLECULAR GENETICS AND METABOLISM 
Novel compound heterozygous pathogenic variants in nucleotide-binding protein like protein (NUBPL) cause leukoencephalopathy with multi-systemic involvement.
 - 2020 Genetics in medicine : official journal of the American College of Medical Genetics 
Genotype-phenotype correlations in recessive titinopathies.
 - 2021 Science (New York, N.Y.) 
RNA-targeted drugs for neuromuscular diseases.
 - 2021 HUMAN MUTATION 
A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing.
 - 2020 Journal of neuromuscular diseases 
Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review.
 - 2021 Neurology. Genetics 
Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries.
 - 2021 Journal of clinical medicine 
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy.
 - 2020 American journal of medical genetics. Part A 
A patient with novel MBOAT7 variant: The cerebellar atrophy is progressive and displays a peculiar neurometabolic profile.
 - 2020 European journal of human genetics : EJHG 
EMQN best practice guidelines for genetic testing in dystrophinopathies.
 - 2020 PLOS ONE 
Genetic testing offer for inherited neuromuscular diseases within the EURO-NMD reference network: A European survey study.
 - 2019 Journal of clinical medicine 
Urinary Stem Cells as Tools to Study Genetic Disease: Overview of the Literature.
 - 2019 Journal of clinical medicine 
Urinary Stem Cells as Tools to Study Genetic Disease: Overview of the Literature.
 - 1994 Neuromuscular disorders : NMD 
Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes.
 - 1996 JOURNAL OF THE NEUROLOGICAL SCIENCES 
Prognostic factors in mild dystrophinopathies.
 - 2017 SCIENTIFIC REPORTS 
Muscle MRI and functional outcome measures in Becker muscular dystrophy.
 - 2012 NEUROLOGY 
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.
 - 1993 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 
Cardiac involvement in Becker muscular dystrophy.
 - 2016 Neuromuscular disorders : NMD 
Becker muscular dystrophy due to an intronic splicing mutation inducing a dual dystrophin transcript.
 - 2021 ANNALS OF NEUROLOGY 
Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale.
 - 2019 Journal of clinical medicine 
The "Usual Suspects": Genes for Inflammation, Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular Dystrophy.
 - 2017 HUMAN MOLECULAR GENETICS 
SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells.
 - 2020 SCIENTIFIC REPORTS 
Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.
 - 2012 NEUROLOGY 
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy
 - 2020 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 
Interpretation of the Epigenetic Signature of Facioscapulohumeral Muscular Dystrophy in Light of Genotype-Phenotype Studies.
 - 2019 Therapeutic advances in neurological disorders 
Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies.
 - 2016 Neuromuscular disorders : NMD 
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
 - 2015 PLOS ONE 
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy.
 - 2011 BMC MEDICAL GENETICS 
Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing.
 - 2011 JOURNAL OF THE NEUROLOGICAL SCIENCES 
Respiratory pattern in an adult population of dystrophic patients.
 - 2011 PEDIATRIC NEUROLOGY 
Neurocognitive profiles in Duchenne muscular dystrophy and gene mutation site.
 - 2012 PHARMACOLOGICAL RESEARCH 
Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients.
 - 2013 PLOS ONE 
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy.
 - 2014 PLOS ONE 
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.
 - 2015 NEUROLOGY 
Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy.
 - 2020 Cellular and molecular life sciences : CMLS 
Noncoding RNAs in Duchenne and Becker muscular dystrophies: role in pathogenesis and future prognostic and therapeutic perspectives.
 - 2011 JOURNAL OF NEUROLOGY 
Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up.
 - 2014 ACTA NEUROPATHOLOGICA COMMUNICATIONS 
MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples.
 - 2016 NEUROLOGY 
The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients.
 - 2018 JAMA NEUROLOGY 
Interpreting Genetic Variants in Titin in Patients With Muscle Disorders.
 - 2015 JOURNAL OF NEUROLOGY 
Centronuclear myopathies: genotype-phenotype correlation and frequency of defined genetic forms in an Italian cohort.
 - 2016 Neuromuscular disorders : NMD 
Histological effects of givinostat in boys with Duchenne muscular dystrophy.
 - 2014 MUSCLE & NERVE 
Ataluren treatment of patients with nonsense mutation dystrophinopathy.
 - 2016 Journal of molecular neuroscience : MN 
New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients.
 - 2018 Genes 
Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients.